about
sameAs
In vitro expression of the HIV-2 genomic RNA is controlled by three distinct internal ribosome entry segments that are regulated by the HIV protease and the Gag polyproteinNon-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityComputational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsStudies of retroviral infection in humanized miceCurrent Trends of HIV Recombination WorldwideCrystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125True story about HIV: theory of viral sequestration and reserve infectionSoluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea PigsElucidation and characterization of oligonucleotide-accessible sites on HIV-2 leader region RNA.Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to the chemokine stromal derived factor 1.Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS modelContribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.Improving HIV-2 detection by a combination of serological and nucleic acid amplification test assays.Molecular investigation of human immunodeficiency virus type 2 subtype a cases in South Korea.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsInhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells.Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infectionsAcquisition of CD4-dependence by CD4-independent SIV passaged in human peripheral blood mononuclear cellsCoinfecting viruses as determinants of HIV disease.Antigenic conservation and immunogenicity of the HIV coreceptor binding siteEffect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine DevelopmentImmunological effect of aqueous extract of Vernonia amygdalina and a known immune booster called immunace(®) and their admixtures on HIV/AIDS clients: a comparative study.Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody.Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.Tits and bits of HIV Tat protein.Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.Changes in the level of apoptosis-related proteins in Jurkat cells infected with HIV-1 versus HIV-2.Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene.
P2860
Q22241577-C1B76134-0780-4CB6-8FDE-02437339C2D6Q24628212-2196B88C-3D29-42FF-9AA5-0A242359DACCQ26777448-B2B078CF-F18C-4E2F-8193-416A00FFB28AQ26849806-8B1D156E-3C37-491B-87D5-4DD96B1B5227Q26865754-A047D456-3DCF-4327-B274-F190941CFF8BQ27667679-B6893DE3-626A-4AB5-B011-7FC57C4DDEFBQ28732833-B4F7C6D4-D90E-4FBD-B87C-AF1790E08611Q30278897-05903B56-B913-4CB6-BD44-AAB9F2649303Q30915689-D9ED1C97-42BE-4EFA-9583-9A9812F1B7B5Q33911849-D7403D66-5FE1-436C-8F81-3EB03B784CFAQ33912052-5BAADA07-D778-4B39-8FF7-8763B21B42A3Q33951963-307F13CA-D214-4D96-B794-C19188F7C4E4Q34046466-CB7E8002-758B-4A6F-9356-B1EBD4758855Q34569035-0795A8A4-C46C-4FCF-B45A-52A4B642657EQ34611466-D35CD97E-C0A3-4B6C-A366-B41C912076FEQ34730950-898284B3-A0B7-402B-902C-F153C09E5363Q34757009-C2B8BD74-16F7-466D-BF59-1DD576BE5224Q34996958-9B890729-BAED-4847-9B14-CE9D29DC8B5DQ35149625-1B036263-4683-4588-8D12-909A33EBA535Q35206272-00D8C811-6786-45F4-80C8-EAE4A403CB85Q35215251-0B628A0D-06B7-4988-9B22-DC3F3E2A4ECFQ35857480-B834234D-6884-4ED5-B143-87BE1C040530Q36162633-D5D7AB61-19C2-4ECF-92EE-3A908FFBBF0FQ36189825-FD650359-701C-4865-9DDC-D791880B5E4AQ36403587-8D6ECB54-02A9-4B9A-B260-713B617AC165Q36506821-63BF953E-BD66-45B5-8111-805ECF081301Q36651031-913226C6-C4CC-4686-BC47-0DAFA096E998Q36719642-3AF8672D-55D9-45A8-A281-349D6F9C59EFQ37378819-1DE452F3-6FEC-4BE5-82AC-E46CA79BD06CQ37546640-DEA72867-7C53-4ACC-98D3-218DF36B763AQ37639557-28BB0112-F048-44CB-90CA-1B3AE45D1E9AQ37682830-4EC98FCD-E8EE-4A78-9F2C-04E230C850D4Q37825906-66A8B726-650E-468E-95AC-E4C3DFD4A05BQ38538043-FE671FBF-3390-483D-9ADB-4A3A5FCF3E21Q39344552-0961DE3E-961A-471D-811A-594EA5475F2FQ39451862-63D72AF5-946D-4B52-8073-80C7F6946B70Q39533357-4074B06F-18CB-4283-8931-89D0705DB401Q39785624-AD143F4A-0544-4EDA-AC17-47F3F7354EE4Q41573062-F93E2558-263F-477E-B42A-2582E4B2D60AQ41761525-131D07A5-0898-4467-B1C6-10FE9C69DD4C
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Human immunodeficiency virus type 2
@ast
Human immunodeficiency virus type 2
@en
Human immunodeficiency virus type 2
@nl
type
label
Human immunodeficiency virus type 2
@ast
Human immunodeficiency virus type 2
@en
Human immunodeficiency virus type 2
@nl
prefLabel
Human immunodeficiency virus type 2
@ast
Human immunodeficiency virus type 2
@en
Human immunodeficiency virus type 2
@nl
P3181
P1476
Human immunodeficiency virus type 2
@en
P2093
Jacqueline D Reeves
Robert W Doms
P304
P3181
P356
10.1099/0022-1317-83-6-1253
P407
P577
2002-06-01T00:00:00Z